RecruitingPhase 2NCT04696523

Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage

Effect of Xenon on Brain Injury, Neurological Outcome and Survival in Patients After Aneurysmal Subarachnoid Hemorrhage


Sponsor

Turku University Hospital

Enrollment

160 participants

Start Date

Apr 22, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

An investigator-initiated clinical drug study Main Objective: To explore neuroprotective properties of xenon in patients after aneurysmal subarachnoid hemorrhage (SAH). Primary endpoint: Global fractional anisotropy of white matter of diffusion tensor imaging (DTI). Hypothesis: White matter damage is less severe in xenon treated patients, i.e. global fractional anisotropy is significantly higher in the xenon group than in the control group as assessed with the 1st magnetic resonance imaging (MRI). After confirmation of aSAH and obtaining a signed assent subjects will be randomized to the following groups: Control group: Standard of Care (SOC) group: Air/oxygen and Normothermia 36.5-37.5°C; Xenon group: Normothermia 36.5-37.5°C +Xenon inhalation in air/oxygen for 24 hours. Brain magnetic resonance imaging techniques will be undertaken to evaluate the effects of the intervention on white and grey matter damage and neuronal loss. Neurological outcome will be evaluated at 3, 12 and 24 months after onset of aSAH symptoms Investigational drug/treatment, dose and mode of administration: 50±2 % end tidal concentration of inhaled xenon in oxygen/air. Comparative drug(s)/placebo/treatment, dose and mode of administration: Standard of care treatment according to local and international consensus reports. Duration of treatment: 24 hours Assessments: Baseline data Information that characterizes the participant's condition prior to initiation of experimental treatment is obtained as soon as is clinically reasonable. These include participant demographics, medical history, vital signs, oxygen saturation, and concentration of oxygen administered. Acute data The collected information will contain quantitative and qualitative data of aSAH patients, as recommended by recent recommendations of the working group on subject characteristics, and including all relevant Common Data Elements (CDE) can be applied. Specific definitions, measurements tools, and references regarding each SAH CDE can be found on the weblink here: https://www.commondataelements.ninds.nih.gov/SAH.aspx#tab=Data\_Standards.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether xenon gas (an inhaled anesthetic) can help protect the brain after a burst blood vessel (aneurysmal subarachnoid hemorrhage) causes a serious brain bleed. Researchers hope this treatment can reduce brain injury in critically ill patients. **You may be eligible if...** - You are 18 or older - You had an aneurysmal brain bleed confirmed by imaging - You are on a breathing machine (intubated) - Your level of consciousness has deteriorated significantly (Hunt-Hess grade 3-5) - Your Glasgow Coma Scale score is between 3 and 12 (when not sedated) - Treatment can begin within 6 hours of symptom onset - Consent can be provided by a family member or legal representative **You may NOT be eligible if...** - Xenon treatment cannot be started in time - Consent cannot be obtained Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGXenon

Xenon arm will be treated with xenon inhalation with endtidal concentration of 50 % in air/oxygen and with standard of care

DRUGair/oxygen

Control group will be treated with air/oxygen


Locations(7)

Aalto University School of Science

Helsinki, Helsinki, Finland

Kuopio University Hospital

Kuopio, Kuopio, Finland

Tampere University Hospital

Tampere, Pirkanmaa, Finland

Turku University Hospital

Turku, Turku, Finland

Elomatic

Turku, Turku, Finland

University of Turku, Turku Bioscience, Analysis of the metabolomics

Turku, Turku, Finland

Örebro University

Örebro, Örebro County, Sweden

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04696523


Related Trials